NCT01010633

Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 406 (actual)
• Sponsor: Bausch & Lomb Incorporated · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is being conducted to compare the safety and efficacy of loteprednol etabonate compared to vehicle for the treatment of postoperative inflammation and pain following cataract surgery.

Conditions

• Inflammation
• Pain

Interventions

Type	Name	Description
DRUG	Vehicle of Loteprednol Etabonate	1 to 2 drops of vehicle administered into the study eye, 4 times a day for approximately 14 days.
DRUG	Loteprednol Etabonate	1 to 2 drops of study drug administered into the study eye, 4 times a day for approximately 14 days.

Timeline

• Start date: 2009-11-01
• Primary completion: 2010-06-01
• Completion: 2010-08-01
• First posted: 2009-11-10
• Last updated: 2012-01-09
• Results posted: 2012-01-09

Locations

1 site across 1 country: United States